drugset / Trial / NCT00735345
Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma
Phase 2
Terminated
50 enrolled
Study Group of Medical Tumour Therapy (AGMT)
Merck Sharp & Dohme LLC · collabSanofi · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is the evaluate the feasibility and safety of chemotherapy induction treatment combined with cetuximab followed by chemoradiotherapy combined with cetuximab in the treatment of patients with non-metastatic esophageal cancer.
Timeline
- Start
- 2008-08
- Primary completion
- 2012-12
- Completion
- 2012-12
Outcome
Outcome not reported
Stopped: “because of safety concerns the study was terminated prematurely”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cetuximab | Monoclonal antibody | 250 mg/m2 | Intravenous |
| Subject | Cisplatin | Other / unclassified | 15 mg/m2 | Intravenous |
| Subject | Docetaxel | Small molecule | 15 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 300 mg/m2 | Intravenous |